The American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) annually provide updates on trends in cancer incidence and death rates in the United States. This year's report highlighted trends in incidence rates for HPV associated cancers and HPV vaccination coverage levels. Two HPV vaccines (bivalent and quadrivalent) have been shown to protect against most cervical cancers in women and one vaccine (quadrivalent) also protects against genital warts and cancers of the anus, vagina and vulva. There is no data available on vaccine efficacy for prevention HPV-associated cancers of the oropharynx.

In order to assess trends in HPV-associated cancer incidence rates and HPV vaccination coverage levels, Ahmedin Jemal, D.V.M., Ph.D., Surveillance Research Program, American Cancer Society, Atlanta, GA., and colleagues examined cancer incidence data reported by the CDC, and NCI, through NAACCR, as well as cancer mortality data from the CDC. The researchers determined trends in age-standardized incidence and death rates for all cancers combined and for the leading cancers among men and women, while HPV vaccination coverage levels during 2008 and 2010 and the prevalence of Papanicolaou (Pap) testing during 2010 were obtained from national surveys.

During 2000-2009, the researchers found that overall cancer death rates in the U.S. continue to decrease (including for lung, colorectal, female breast, and prostate cancers), but that death rates have increased for cancers of the liver, pancreas, uterine corpus, and melanoma of the skin among males. The incidence rates for these cancers continued to increase as well, including for some cancers associated with HPV infection. Nationally, 32.0% of females aged 13-17 years had received three doses of the HPV vaccine in 2010 showing the necessity for increased efforts to increase HPV vaccination coverage. "Continued monitoring of incidence and mortality trends for all cancers is warranted to inform cancer prevention and control policies and programs," the authors conclude.

In an accompanying editorial, Marc Brisson, Ph.D., Centre de recherche du CHU de Québec, Hôpital Saint-Sacrement, Québec, Canada, and colleagues write that HPV vaccination efforts should be focused on females because it's been predicted to be the most effective way to ensure population-level vaccine effectiveness. "Finding ways to increasing vaccine uptake is a key priority for HPV-related public health research in the United States."

Note: If no author is given, the source is cited instead.

• Vaccines
• Breast Cancer
• Men's Health
• Skin Cancer
• Cancer
• Colon Cancer

• HPV vaccine
• Pap smear
• HPV
• Cervical cancer
• MMR vaccine
• Flu vaccine